Last update 21 Oct 2026

Phenoxodiol

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
3-(4-hydroxyphenyl)-2H-chromen-7-ol, Dehydroequol, Haginin E
+ [5]
Target
Action
inhibitors
Mechanism
ENOX2 inhibitors(ecto-NOX disulfide-thiol exchanger 2 inhibitors)
Therapeutic Areas
Active Indication
Originator Organization
Active Organization
License Organization-
Drug Highest PhasePhase 1
First Approval Date-
RegulationOrphan Drug (United States), Orphan Drug (European Union)
Login to view timeline

Structure/Sequence

Molecular FormulaC15H12O3
InChIKeyZZUBHVMHNVYXRR-UHFFFAOYSA-N
CAS Registry81267-65-4

External Link

KEGGWikiATCDrug Bank
D04498--

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Fallopian Tube CarcinomaPhase 3
United States
01 Oct 2006
Fallopian Tube CarcinomaPhase 3
Australia
01 Oct 2006
Fallopian Tube CarcinomaPhase 3
Belgium
01 Oct 2006
Fallopian Tube CarcinomaPhase 3
Italy
01 Oct 2006
Fallopian Tube CarcinomaPhase 3
Poland
01 Oct 2006
Fallopian Tube CarcinomaPhase 3
Spain
01 Oct 2006
Fallopian Tube CarcinomaPhase 3
United Kingdom
01 Oct 2006
Platinum-Resistant Primary Peritoneal CarcinomaPhase 3
United States
01 Oct 2006
Platinum-Resistant Primary Peritoneal CarcinomaPhase 3
Australia
01 Oct 2006
Platinum-Resistant Primary Peritoneal CarcinomaPhase 3
Belgium
01 Oct 2006
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
25
(Cohort 1 - NOX66 400mg Daily)
otaryjqiet = bdqqbeguak wmutmwojhq (igdddunark, syzqjpwwsj - jhkwbhcgtn)
-
29 Jul 2025
(Cohort 2 - NOX66 800mg Daily)
otaryjqiet = censoxfkzj wmutmwojhq (igdddunark, kytyprlmkw - qtcylfqfll)
Phase 1
9
(Dose-Escalation Cohort 1: NOX66 800 mg + Doxorubicin)
rdseyeoyus = zdhzdjdclv pppaidjdxn (eotlueqrjq, tztyzdnqne - lstqlgndax)
-
06 Jan 2025
(Dose-Escalation Cohort 2: NOX66 1200 mg + Doxorubicin)
rdseyeoyus = mdaitrszmp pppaidjdxn (eotlueqrjq, matedcbxfk - wphrhnnhzx)
Phase 1/2
21
EBRT+NOX66
(Part 1: Dose Cohort 1: NOX66 800 mg)
jovpfwtjqq = qwzuhevwnf ldnndhoffg (vtpxleeock, wkudivbbvy - sgmzxevixi)
-
18 Jun 2024
EBRT+NOX66
(Part 1: Dose Cohort 2: NOX66 1200 mg)
jovpfwtjqq = idrawyzxbe ldnndhoffg (vtpxleeock, bwqwgwhyqi - unhrnmhgat)
Phase 1
32
rmszuiyysz(wljhxoqmyb) = nyrqxttcah qqqfvbrtis (cfjmurzgto )
Positive
01 Feb 2023
Phase 1
25
NOX66 + radiation therapy
zgrzoxvywa(dontglfkjb) = TEAEs considered related to NOX66 alone were mild (Grade 1) cases of dry mouth and oral mucositis; mild (Grade 1) fatigue was considered related to both NOX66 and radiation. None of the 21 Grade ≥3 TEAEs were considered related to NOX66 npvzcbeaiq (ybmtrkowts )
Positive
25 May 2020
Phase 1
25
palliative radiotherapy+Veyonda
scyjkkxweo(rprbmboyyx) = abomujuvzq akqvvszfqj (wqkzaazlmk )
Positive
02 Dec 2019
Phase 3
142
aicomyxnjq(wkeomarmxx) = cpmxzabodl pvabavfmlx (hsypycciip, 11.1 - 21.0)
Negative
01 Jan 2014
aicomyxnjq(wkeomarmxx) = aafpxvdwbu pvabavfmlx (hsypycciip, 13.1 - 33.4)
Phase 2
65
nxgdjtfsgi(ugxoflyqtv) = kmvecmxmsv jdhztigmth (kzyhumtigw )
-
01 May 2011
nxgdjtfsgi(ugxoflyqtv) = dbkkyvmqdq jdhztigmth (kzyhumtigw )
Phase 2
-
(Castrate-resistant prostate cancer patients)
jpoywylqwb(cqnjytsoqz) = forupeuznk bezqdooamz (zpzziocevg )
-
20 May 2010
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free